Speaker illustration

Doctor Ju-Hee Lee

Chong Kun Dang Pharm., Yongin (Korea (Republic of))

I am a head of Pharmacology at CKD Pharm, Korea. I did my post doc training at Memorial Sloan Kettering Cancer Center at NY, USA and after that, since 2013, I have been working at CKD Pharm. My goal is to develop a novel therapy for human diseases including cardiovascular diseases, oncology and metabolic diseases.

CKD-510, A Non-hydroxamic Acid Hdac6 Inhibitor, For Treatment Of Atrial Fibrillation.

Event: ESC Congress 2022

Topic: Antiarrhythmic Pharmacotherapy

Session: Basic and Translational Late-Breaking Science 2


This platform is supported by

logo Novo Nordisk